Measles and rubella elimination country profile Ukraine



Measles elimination status

2016 endemic 2017 endemic



Source:European Regional Verification Commission for Measles and Rubella Elimination (RVC) meeting report: www.euro.who.int/7thrvc

Measles and rubella surveillance



Source: WHO/UNICEF Joint Reporting Form on Immunization, 2017

Measles and rubella immunization schedule, 2017

	Vaccine	Schedule	Year of introduction			
MCV1	MMR	12 months	MCV2	2001		
MCV2	MMR	6 years	6 years RCV			
Ν	Measles vaccination in school					

Source: Immunization schedule, WHO, Data and Statistics, Immunization Monitoring and Surveillance (http://www.who.int/immunization/monitoring_surveillance/data/en/) MMR = measles-mumps-rubella vaccine; MCV1 = first dose measles-containing vaccine; MCV2 = second dose measles-containing vaccine; RCV = rubella-containing vaccine

Definition used for an outbreak

Several cases (3 and more) that are epidemiologically linked between each other by infection source

Source: Measles and rubella elimination Annual Status Update report, 2017



Rubella elimination status




Source:European Regional Verification Commission for Measles and Rubella Elimination (RVC) meeting report: www.euro.who.int/7thrvc

Demographic information, 2017

Total population	44 222 947
< 1 year old	429 937
< 5 years old	2 303 013

Source: World Population Prospects: The 2017 Revision, New York, United Nations


Measles and rubella cases and immunization coverage, 2008–2017



Source: Disease incidence and immunization coverage (WUENIC), WHO, Data and Statistics, Immunization Monitoring and Surveillance (http://www.who.int/immunization/monitoring_surveillance/data/en/) MCV1 = first dose of measles-containing vaccine

MCV2= second dose of measles-containing vaccine


Confirmed measles cases by month of onset, 2013-2017



Source: CISID 2017




Measles cases by first subnational level, 2017





Measles genotypes by first subnational level, 2017

Note: The dots in the maps are placed randomly within the administrative regions. Map disclaimer: The boundaries and names shown and the designations used on the maps do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement



Measles cases by age group and vaccination status, 2017

Sources of infection, 2017

	Measles	Rubella
Imported	1	0
Import-related	0	0
Unknown/ Not reported	0	0
Endemic	4781	160

Source: Measles and rubella elimination Annual Status Update report, 2017

Supplementary immunization activities

Year	Target age	Vaccine used	% Coverage
2017	1-9Y	MMR	57%
2017	6-9Y	MMR	67%

Source: Supplementary immunization activities, WHO, Data and Statistics, Immunization Monitoring and Surveillance (http://www.who.int/immunization/monitoring_surveillance/data/en/) MMR = measles-mumps-rubella vaccine ND = Data not available

Information on CRS, 2017



CRS = congenital rubella syndrome



Measles incidence, epidemiologic and virologic characteristics, 2013-2017

	Suspected	Confirmed measles cases				Discarded as	Measles	Genotypes
	measles cases	Laboratory	Epi- linked	Clinically	Total	non- measles	incidence	detected
2013	3978	1300	0	2009	3309	669	72.8	D4,D8
2014	2800	857	520	939	2326	474	50.8	D4,D8
2015	235	35	0	70	105	130	2.4	ND
2016	638	47	21	34	102	536	2.4	D8
2017	5410	1984	926	1872	4782	628	112.3	D8

urce: Measles and rubella elimination Annual Status Update report, 2013-2017 Incidence calculated per 1 million population

ND = Data not available: NA= Not applicable

Rubella incidence, epidemiologic and virologic characteristics, 2013-2017

		Suspected rubella	Confirmed rubella cases				Discarded as	Rubella	Genotypes
		cases	Laboratory	Epi- linked	Clinically	Total	non- rubella	incidence	detected
20	13	2193	362	0	909	1271	922	28	2B
20	14	2013	304	122	915	1341	672	29	ND
20	15	600	15	0	232	247	353	5.8	ND
20:	16	330	2	0	146	150	180	3.5	ND
20	17	350	7	12	141	160	190	3.8	ND

ource: Measles and rubella elimination Annual Status Update report, 2013-2017 Incidence calculated per 1 million population ND = Data not available: NA= Not applicable

Measles surveillance and laboratory performance indicators, 2013-2017

	Discarded non- measles rate	% 1st sub- national unit with ≥ 2 discarded cases	% cases with adequate laboratory investigation	% origin of infection known	# specimen tested for measles	% positive for measles	Rate of viral detection	% WHO and proficient labs
2013	1.5	ND	39.3%	ND	1 007	61.9%	14	100%
2014	1.1	ND	51.4%	ND	517	39.9%	4	100%
2015	7.8	ND	82.3%	1.9%	326	10.7%	0	100%
2016	1.3	ND	100%	39.2%	638	7.4%	0	100%
2017	1.5	12%	50.1%	100%	2712	73.2%	24.2%	62.1%

Source: ASU 2013-2017 ND = Data not available; NA= Not applicable

A proficient laboratory is WHO accredited and/or has an established quality assurance programme with oversight by a WHO accredited laboratory

Rubella surveillance and laboratory performance indicators, 2013-2017

	Discarded non- rubella rate	% 1st sub- national unit with ≥ 2 discarded cases	% cases with adequate laboratory investigtion	% origin of infection known	# specimen tested for rubella	% positive for rubella	Rate of viral detection	% WHO and proficient labs
2013	2	ND	28.5%	ND	478	29.7%	ND	100%
2014	1.5	ND	42.2%	ND	450	30%	ND	100%
2015	0.8	ND	56.3%	ND	338	4.4%	ND	100%
2016	0.5	ND	100%	ND	632	0.3%	ND	100%
2017	0.4	ND	19.4%	100%	68	10.3%	ND	80.9%

Source: ASU 2013-2017 ND = Data not available; NA= Not applicable

A proficient laboratory is WHO accredited and/or has an established quality assurance programme with oversight by a WHO accredited laboratory

RVC comments, based on 2017 reporting

The Regional Verification Commission for Measles and Rubella Elimination (RVC) commends Ukraine on efforts to increase immunization coverage, but with ongoing measles outbreak still urges further steps to achieve and maintain universal high vaccination coverage with 2 doses of MRCV. Surveillance sensitivity, laboratory testing and genotyping needs to be strengthened and better documented in ASU.

Source: Regional Verification Commission for Measles and Rubella Elimination (RVC) meeting report (www.euro.who.int/7thrvc)

Surveillance performance indicators and targets

- a. Rate of discarded cases: at least 2 discarded measles or rubella cases per 100 000 population
- b. % cases with adequate laboratory investigation: $\geq 80\%$
- c. % origin of infection known: $\geq 80\%$
- d. Rate of viral detection: $\geq 80\%$